• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2026

    3/11/26 4:02:00 PM ET
    $KEQU
    Medical Specialities
    Industrials
    Get the next $KEQU alert in real time by email

    STATESVILLE, N.C., March 11, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2026.

    Kewaunee Scientific Corporation (PRNewsFoto/Kewaunee Scientific Corporation)

    Fiscal Year 2026 Third Quarter Results:

    Sales during the third quarter of fiscal year 2026 were $69,399,000, an increase of 3.3% compared to sales of $67,167,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,604,000 compared to $1,275,000 for the prior year quarter, an increase of 25.8%. Net earnings were $692,000 compared to net earnings of $1,354,000 for the prior year quarter. EBITDA1 for the quarter was $3,795,000 compared to $3,734,000 for the prior year quarter. Diluted earnings per share were $0.23 compared to diluted earnings per share of $0.45 in the prior year quarter.

    The Company's order backlog was $183.2 million on January 31, 2026, as compared to $221.6 million on January 31, 2025, and $214.6 million on April 30, 2025.

    Domestic Segment - Domestic sales for the quarter were $50,953,000, a decrease of 2.0% from sales of $51,976,000 in the prior year quarter. Domestic segment net earnings were $2,290,000 compared to $2,876,000 in the prior year quarter. Domestic segment EBITDA was $4,096,000 compared to $5,249,000 for the prior year quarter. Segment profitability was impacted during the period by lower manufacturing volumes across the laboratory construction portion of the business.

    International Segment - International sales for the quarter were $18,446,000, an increase of 21.4% from sales of $15,191,000 in the prior year quarter. International segment net earnings were $1,256,000 compared to $476,000 in the prior year quarter. International segment EBITDA was $1,963,000 compared to $760,000 for the prior year quarter. International profitability increased when compared to the prior year period due to higher billings, principally in the Indian market.

    Corporate Segment – Corporate segment pre-tax net loss was $3,059,000 for the quarter, as compared to a pre-tax net loss of $3,025,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($2,264,000) compared to corporate segment EBITDA of ($2,275,000) for the prior year quarter. Corporate segment EBITDA remained relatively flat as the Company continues to make strategic investments in people, processes, and technology to further build out its Corporate platform and support continued growth.

    Total cash on hand on January 31, 2026, was $10,347,000, as compared to $17,164,000 on April 30, 2025. Working capital was $54,793,000, as compared to $58,441,000 at the end of the third quarter last year and $64,651,000 on April 30, 2025.

    The Company had short-term debt of $7,351,000 as of January 31, 2026, as compared to $4,773,000 on April 30, 2025. Long-term debt was $42,316,000 on January 31, 2026, as compared to $60,730,000 on April 30, 2025. The building lease from the Company's December 2021 sale-leaseback transaction accounts for $25,988,000 of the long-term debt on January 31, 2026, and $26,632,000 of the long-term debt on April 30, 2025. Long-term debt, net of the sale-leaseback transaction, was $16,328,000 on January 31, 2026, as compared to $34,098,000 on April 30, 2025. The Company's debt-to-equity ratio on January 31, 2026, was 0.68-to-1, as compared to 0.99-to-1 on April 30, 2025. The Company's debt-to-equity ratio, net of the sale-leaseback transaction, on January 31, 2026, was 0.31-to-1, as compared to 0.57-to-1 on April 30, 2025.

    "Following the successful turnaround of the business, we embarked on a strategy that accelerated inorganic growth, which led to the successful completion of the Company's acquisition of Nu Aire," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "Since then, our teams have worked diligently to integrate Nu Aire into the Kewaunee family and position the business for meaningful growth and EBITDA contribution. We have also continued to invest in our corporate platform to support the next phase of our inorganic growth strategy. These investments include strengthening our corporate team, implementing a robust financial consolidation system, and enhancing our readiness to comply with the SEC's accelerated reporting requirements."

    "As is traditionally the case," Hull continued, "our third quarter results often represent our softest quarter due to the impact of the holiday schedule in the United States, a general slowdown of construction schedules in the winter months, and customers looking to wrap up any construction projects before the calendar year-end. This trend was further exacerbated by significant geopolitical and economic uncertainty, and by the volatility in project delivery timelines that we have previously discussed. Although the construction-related portion of our business has been soft this fiscal year, the addition of Nu Aire's end-user containment products has helped offset that softness. This dynamic validates our growth and diversification strategy and underscores the strength and resilience of our now broader laboratory products portfolio."

    "I am proud of how our team has responded to a year of challenging global dynamics. That our company was still able to deliver year-over-year growth on an as-reported basis underscores the value of our strategy and our commitment to long-term value creation."

    ______________________

    1 EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure.

     

    EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA Reconciliation

    (Unaudited)

    ($ in thousands)

     

    Quarter Ended January 31, 2025



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                  2,876



    $                    476



    $                (1,998)



    $                  1,354

    Add/(Less):

















    Interest Expense



    322



    26



    789



    1,137

    Interest Income



    (1)



    (130)



    (81)



    (212)

    Income Taxes



    638



    281



    (1,027)



    (108)

    Depreciation and Amortization



    1,414



    107



    42



    1,563

    EBITDA



    $                  5,249



    $                    760



    $                (2,275)



    $                  3,734

    Professional Fees2



    1,012



    —



    982



    1,994

    Adjusted EBITDA



    $                  6,261



    $                    760



    $                (1,293)



    $                  5,728



















    Quarter Ended January 31, 2026



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                  2,290



    $                  1,256



    $                (2,854)



    $                    692

    Add/(Less):

















    Interest Expense



    307



    16



    789



    1,112

    Interest Income



    (2)



    (117)



    (15)



    (134)

    Income Taxes



    22



    711



    (205)



    528

    Depreciation and Amortization



    1,479



    97



    21



    1,597

    EBITDA



    $                  4,096



    $                  1,963



    $                (2,264)



    $                  3,795

    Professional & Other Fees3



    —



    —



    189



    189

    Adjusted EBITDA



    $                  4,096



    $                  1,963



    $                (2,075)



    $                  3,984



















    Year to Date January 31, 2025



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                10,271



    $                  1,295



    $                (5,011)



    $                  6,555

    Add/(Less):

















    Interest Expense



    1,176



    66



    809



    2,051

    Interest Income



    (1)



    (437)



    (410)



    (848)

    Income Taxes



    2,643



    807



    (2,450)



    1,000

    Depreciation and Amortization



    2,736



    317



    131



    3,184

    EBITDA



    $                16,825



    $                  2,048



    $                (6,931)



    $                11,942

    Professional & Other Fees2



    1,012



    —



    3,253



    4,265

    Adjusted EBITDA



    $                17,837



    $                  2,048



    $                (3,678)



    $                16,207



















    Year to Date January 31, 2026



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                10,609



    $                  2,540



    $                (6,919)



    $                  6,230

    Add/(Less):

















    Interest Expense



    931



    39



    2,261



    3,231

    Interest Income



    (4)



    (428)



    (54)



    (486)

    Income Taxes



    2,482



    1,435



    (1,713)



    2,204

    Depreciation and Amortization



    4,366



    292



    68



    4,726

    EBITDA



    $                18,384



    $                  3,878



    $                (6,357)



    $                15,905

    Professional & Other Fees3



    —



    —



    763



    763

    Adjusted EBITDA



    $                18,384



    $                  3,878



    $                (5,594)



    $                16,668

    _____________________

    2 Professional and other fees incurred during the three and nine months ended January 31, 2025 related to the Company's acquisition of Nu Aire, Inc. ("Nu Aire"), which closed on November 1, 2024

    3 Professional and other fees incurred during the three and nine months ended January 31, 2026 related to the Company's integration of its newly acquired subsidiary, Nu Aire

     

    Adjusted Consolidated Statement of Operations Reconciliation

    (Unaudited)

    ($ in thousands, except per share amounts)



    Three Months Ended January 31,



    As Reported

    2026



    Professional &

    Other Fees4



    Adjusted

    2026



    Adjusted

    2025

    Net sales

    $      69,399



    $             —



    $      69,399



    $      67,167

    Cost of products sold

    50,854



    —



    50,854



    47,934

    Gross profit

    18,545



    —



    18,545



    19,233

    Operating expenses

    15,963



    189



    15,774



    14,469

    Operating profit

    2,582



    189



    2,771



    4,764

    Other income, net

    134



    —



    134



    162

    Interest expense

    (1,112)



    —



    (1,112)



    (1,137)

    Profit before income taxes

    1,604



    189



    1,793



    3,789

    Income tax (benefit) expense

    528



    44



    572



    502

    Net earnings

    1,076



    145



    1,221



    3,287

    Less: Net earnings attributable to the non-controlling interest

    384



    —



    384



    29

    Net earnings attributable to Kewaunee Scientific Corporation

    $           692



    $           145



    $           837



    $        3,258

















    Net earnings per share attributable to Kewaunee Scientific Corporation stockholders















    Basic

    $          0.24



    $          0.05



    $          0.29



    $          1.13

    Diluted

    $          0.23



    $          0.05



    $          0.28



    $          1.09

     



    Nine Months Ended January 31,



    As Reported

    2026



    Professional &

    Other Fees4



    Adjusted

    2026



    Adjusted

    2025

    Net sales

    $    210,599



    $             —



    $    210,599



    $    163,324

    Cost of products sold

    151,404



    —



    151,404



    117,651

    Gross profit

    59,195



    —



    59,195



    45,673

    Operating expenses

    47,696



    763



    46,933



    31,954

    Operating profit

    11,499



    763



    12,262



    13,719

    Other income, net

    709



    —



    709



    752

    Interest expense

    (3,231)



    —



    (3,231)



    (2,051)

    Profit before income taxes

    8,977



    763



    9,740



    12,420

    Income tax (benefit) expense

    2,204



    174



    2,378



    2,161

    Net earnings

    6,773



    589



    7,362



    10,259

    Less: Net earnings attributable to the non-controlling interest

    543



    —



    543



    81

    Net earnings attributable to Kewaunee Scientific Corporation

    $        6,230



    $           589



    $        6,819



    $      10,178

















    Net earnings per share attributable to Kewaunee Scientific Corporation stockholders















    Basic

    $          2.18



    $          0.21



    $          2.38



    $          3.55

    Diluted

    $          2.09



    $          0.20



    $          2.29



    $          3.42

    _______________________

    4 Professional and other fees incurred during the three and nine months ended January 31, 2026 related to the Company's integration of its newly acquired subsidiary, Nu Aire, including the estimated tax impact

    About Non-GAAP Measures 

    The Company includes non-GAAP financial measures such as adjusted net earnings and adjusted net earnings per share, in the information provided with this press release as supplemental information relating to its operating results. Adjusted net earnings represents GAAP net earnings adjusted for professional and other fees related to the integration of the Company's newly acquired subsidiary, Nu Aire, Inc., and the corresponding tax impact. This financial information is not in accordance with, or an alternative for, GAAP-compliant financial information and may be different from the operating or non-GAAP financial information used by other companies. The Company believes that this presentation of adjusted net earnings and adjusted net earnings per share provides useful information to investors regarding certain additional financial and business trends relating to its financial condition and results of operations.

    EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. Adjusted EBITDA and Adjusted Segment EBITDA are calculated as EBITDA or Segment EBITDA less the impact of the professional and other fees related to the Company's integration of its newly acquired subsidiary,  Nu Aire, Inc., as discussed in more detail above. We believe EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to interest expense and interest income, income taxes, depreciation, amortization or the costs incurred related to the integration of Nu Aire, Inc., which can vary significantly between companies depending upon many factors. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA can vary among companies. The amounts included in the EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA calculations, however, are derived from amounts included in the historical consolidated statements of operations. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company's operating performance, or as an alternative to operating cash flows as a measure of liquidity.

    About Kewaunee Scientific

    Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. 

    Kewaunee Scientific's newly acquired subsidiary, Nu Aire, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, Nu Aire's headquarters and manufacturing facilities are located in Plymouth, Minnesota, with additional manufacturing capabilities located in Long Lake, Minnesota. The Company also maintains a warehouse partnership in the Netherlands and OEM partnerships in China.

    Learn more at the companies' websites, located at https://www.kewaunee.com and https://www.nuaire.com/. 

    This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the Nu Aire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such a difference are described under the caption "Risk Factors," in Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2025, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at www.kewaunee.com and on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Kewaunee Scientific Corporation

    Condensed Consolidated Statements of Operations

    (Unaudited)

    ($ and shares in thousands, except per share amounts)

     



    Three Months Ended

    January 31,



    Nine Months Ended

    January 31,



    2026



    2025



    2026



    2025

    Net sales

    $       69,399



    $       67,167



    $    210,599



    $     163,324

    Cost of products sold

    50,854



    48,788



    151,404



    118,505

    Gross profit

    18,545



    18,379



    59,195



    44,819

    Operating expenses

    15,963



    16,129



    47,696



    35,560

    Operating profit

    2,582



    2,250



    11,499



    9,259

    Other income, net

    134



    162



    709



    428

    Interest expense

    (1,112)



    (1,137)



    (3,231)



    (2,051)

    Profit before income taxes

    1,604



    1,275



    8,977



    7,636

    Income tax  expense (benefit)

    528



    (108)



    2,204



    1,000

    Net earnings

    1,076



    1,383



    6,773



    6,636

    Less: Net earnings attributable to the non-controlling interest

    384



    29



    543



    81

    Net earnings attributable to Kewaunee Scientific Corporation

    $            692



    $         1,354



    $        6,230



    $         6,555

















    Net earnings per share attributable to Kewaunee Scientific Corporation stockholders















    Basic

    $           0.24



    $           0.47



    $          2.18



    $           2.29

    Diluted

    $           0.23



    $           0.45



    $          2.09



    $           2.20

    Weighted average number of common shares outstanding















    Basic

    2,866



    2,872



    2,861



    2,864

    Diluted

    2,983



    2,995



    2,979



    2,979

       

    Kewaunee Scientific Corporation

    Condensed Consolidated Balance Sheets

    ($ in thousands)

     



    January 31, 2026



    April 30, 2025



    (Unaudited)





    Assets







    Cash and cash equivalents

    $            8,153



    $          14,942

    Restricted cash

    2,194



    2,222

    Receivables, less allowances

    54,131



    62,384

    Inventories

    32,907



    32,849

    Prepaid expenses and other current assets

    6,193



    5,966

    Total Current Assets

    103,578



    118,363

    Net property, plant and equipment

    22,610



    23,174

    Right of use assets

    10,449



    12,965

    Deferred income taxes

    3,570



    3,994

    Net intangible assets

    16,679



    17,831

    Goodwill

    12,487



    12,487

    Other assets

    6,588



    5,840

    Total Assets

    $        175,961



    $        194,654









    Liabilities and Stockholders' Equity







    Short-term borrowings

    $            1,542



    $              986

    Current portion of lease obligations

    3,248



    3,371

    Current portion of financing liability

    847



    788

    Current portion of term loans

    4,893



    2,903

    Accounts payable

    23,641



    27,033

    Other current liabilities

    14,614



    18,631

    Total Current Liabilities

    48,785



    53,712

    Long-term portion of lease obligations

    6,796



    8,946

    Long-term portion of financing liability

    25,988



    26,632

    Long-term portion of seller note

    —



    23,537

    Long-term portion of term loans

    16,028



    10,412

    Other non-current liabilities

    5,836



    5,170

    Total Liabilities

    103,433



    128,409

    Kewaunee Scientific Corporation Equity

    70,675



    64,457

    Non-controlling interest

    1,853



    1,788

    Total Stockholders' Equity

    72,528



    66,245

    Total Liabilities and Stockholders' Equity

    $        175,961



    $        194,654

         

     Contact:         

    Donald T. Gardner III



    704/871-3274

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kewaunee-scientific-reports-results-for-third-quarter-of-fiscal-year-2026-302711429.html

    SOURCE Kewaunee Scientific Corporation

    Get the next $KEQU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KEQU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KEQU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gehl Keith M bought $35,000 worth of shares (1,000 units at $35.00), increasing direct ownership by 6% to 18,500 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    4/7/25 10:57:11 AM ET
    $KEQU
    Medical Specialities
    Industrials

    Director Gehl Keith M bought $22,500 worth of shares (500 units at $45.00), increasing direct ownership by 3% to 17,500 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    3/24/25 4:32:54 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Director Gehl Keith M bought $19,747 worth of shares (403 units at $49.00), increasing direct ownership by 2% to 17,000 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    3/18/25 3:20:26 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2026

    STATESVILLE, N.C., March 11, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2026. Fiscal Year 2026 Third Quarter Results:Sales during the third quarter of fiscal year 2026 were $69,399,000, an increase of 3.3% compared to sales of $67,167,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,604,000 compared to $1,275,000 for the prior year quarter, an increase of 25.8%. Net earnings were $692,000 compared to net earnings of $1,354,000 for the prior year quarter. EBITD

    3/11/26 4:02:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific and Nu Aire Inc. to Attend analytica 2026 in Munich

    STATESVILLE, N.C., March 3, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced that the Company will attend the 2026 analytica tradeshow and conference, taking place in Munich from March 24-27. Kewaunee will be joined by the Company's recently acquired subsidiary, Nu Aire, Inc. (NuAire), a proven leader in containment and biosafety technologies. Together, they will showcase a complete and complementary portfolio of laboratory infrastructure and safety-focused solutions designed to support the needs of modern lab environments worldwide.Established

    3/3/26 4:01:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific to Report Results for Third Quarter Fiscal Year 2026

    STATESVILLE, N.C., Feb. 25, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced that the Company plans to release its third quarter fiscal year 2026 financial results on Wednesday, March 11, 2026 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products

    2/25/26 4:02:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    SEC Filings

    View All

    Kewaunee Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    3/11/26 4:05:04 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    2/25/26 4:06:39 PM ET
    $KEQU
    Medical Specialities
    Industrials

    SEC Form 10-Q filed by Kewaunee Scientific Corporation

    10-Q - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    12/12/25 9:41:25 AM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CEO Hull Thomas David Iii sold $81,638 worth of shares (2,177 units at $37.50), decreasing direct ownership by 6% to 33,000 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    1/8/26 9:09:31 AM ET
    $KEQU
    Medical Specialities
    Industrials

    Chief Financial Officer Gardner Donald T. Iii sold $75,140 worth of shares (2,000 units at $37.57), decreasing direct ownership by 17% to 9,564 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    1/7/26 3:59:57 PM ET
    $KEQU
    Medical Specialities
    Industrials

    President, CEO Hull Thomas David Iii sold $24,790 worth of shares (658 units at $37.67), decreasing direct ownership by 2% to 35,177 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    1/2/26 1:03:17 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Financials

    Live finance-specific insights

    View All

    Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter

    STATESVILLE, N.C., June 25, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its fourth quarter and its fiscal year ended April 30, 2025. Fiscal Year 2025 Fourth Quarter Results Sales during the fourth quarter of fiscal year 2025 were $77,148,000, an increase of 36.1% compared to sales of $56,702,000 from the prior year's fourth quarter. Pre-tax earnings for the quarter were $7,149,000 compared to $1,347,000 for the prior year quarter. Net earnings for the quarter were $4,850,000 compared to net earnings of $11,026,000 for the prio

    6/25/25 6:22:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

    STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

    3/12/25 4:16:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2025

    STATESVILLE, N.C., Dec. 11, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2024. Fiscal Year 2025 Second Quarter Results: Sales during the second quarter of fiscal year 2025 were $47,764,000, a decrease of 5.3% compared to sales of $50,436,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,931,000 compared to $4,845,000 for the prior year quarter, a decrease of 18.9%. Net earnings were $3,008,000 compared to net earnings of $2,732,000 for the prior year quarter.

    12/11/24 4:04:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Leadership Updates

    Live Leadership Updates

    View All

    Kewaunee Scientific Announces Appointment of J. Jette Campbell to Board of Directors

    STATESVILLE, N.C., Sept. 11, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU), a recognized leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, announces the appointment of J. Jette Campbell, CPA, to its Board of Directors, effective September 10, 2025. Campbell brings decades of experience guiding organizations through significant growth and transformation. Campbell's impressive career spans leadership roles at global companies such as PepsiCo, Frito-Lay, and Griffin LLC, a DuPont venture. He also

    9/11/25 4:03:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kewaunee Scientific Corporation

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    11/1/24 9:14:13 AM ET
    $KEQU
    Medical Specialities
    Industrials

    SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    2/9/24 11:44:29 AM ET
    $KEQU
    Medical Specialities
    Industrials

    SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    2/9/24 9:59:14 AM ET
    $KEQU
    Medical Specialities
    Industrials